Advanced search
Publication Cover
Annals of Medicine Volume 44, 2012 - Issue 4
Submit an article Journal homepage
5,815
Views
207
CrossRef citations to date
0
Altmetric
Research Article

A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials

Giovanni MussoGradenigo Hospital, Turin, ItalyCorrespondence[email protected]
,
Roberto GambinoDepartment of Internal Medicine, University of Turin, Italy
,
Maurizio CassaderDepartment of Internal Medicine, University of Turin, Italy
&
Gianfranco PaganoDepartment of Internal Medicine, University of Turin, Italy
Pages 375-393 | Received 07 Nov 2010, Accepted 23 Dec 2010, Published online: 15 Apr 2011

Citations (207)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (27)

Khaled Nashar & Patricia Khalil. (2022) Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus on Patient Selection and Clinical Perspectives. International Journal of Nephrology and Renovascular Disease 15, pages 289-308.
Read now
Nasir Shah, Vlado Perkovic & Sradha Kotwal. (2022) Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria. Expert Review of Clinical Pharmacology 15:7, pages 827-842.
Read now
Xinhui Feng, Yuqi Zheng, Haochen Guan, Xun Zhou, Ying Xu, Xiaoli Zhang, Chensheng Fu, Jing Xiao & Zhibin Ye. (2021) The Association between Urinary Glucose and Renal Uric Acid Excretion in Non-diabetic Patients with Stage 1-2 Chronic Kidney Disease. Endocrine Research 46:1, pages 28-36.
Read now
Emir Muzurović & Dimitri P Mikhailidis. (2020) Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. Expert Opinion on Pharmacotherapy 21:17, pages 2125-2135.
Read now
Sempastian Filippas-Ntekouan, Vasilios Tsimihodimos, Theodosios Filippatos, Theodora Dimitriou & Moses Elisaf. (2018) SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opinion on Drug Metabolism & Toxicology 14:11, pages 1113-1121.
Read now
Christos V. Rizos, Theodosios D. Filippatos & Moses S. Elisaf. (2018) Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 14:1, pages 117-125.
Read now
Sebastian Filippas-Ntekouan, Theodosios D. Filippatos & Moses S. Elisaf. (2018) SGLT2 inhibitors: are they safe?. Postgraduate Medicine 130:1, pages 72-82.
Read now
Serge Jabbour. (2017) Durability of response to dapagliflozin: a review of long-term efficacy and safety. Current Medical Research and Opinion 33:9, pages 1685-1696.
Read now
A. Avogaro, A. Giaccari, P. Fioretto, S. Genovese, F. Purrello, F. Giorgino & S. Del Prato. (2017) A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. Expert Review of Clinical Pharmacology 10:7, pages 763-772.
Read now
Vasilios Tsimihodimos, Theodosios D. Filippatos & Moses S. Elisaf. (2017) Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. Expert Opinion on Drug Metabolism & Toxicology 13:4, pages 399-408.
Read now
R. Devi, Ghanshyam Mali, Indrani Chakraborty, Mazhuvancherry Kesavan Unnikrishnan & Suhaj Abdulsalim. (2017) Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Postgraduate Medicine 129:3, pages 382-392.
Read now
Christian W. Mende. (2017) Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Current Medical Research and Opinion 33:3, pages 541-551.
Read now
Kalliopi Pafili, Efstratios Maltezos & Nikolaos Papanas. (2016) Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 12:11, pages 1367-1380.
Read now
Rizwana Parveen, Nidhi Bharal Agarwal, Neelam Kaushal, Ghanshyam Mali & Sheikh Raisuddin. (2016) Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. Expert Opinion on Pharmacotherapy 17:1, pages 105-115.
Read now
Masatoshi Hasegawa, Yukihiro Chino, Nobuko Horiuchi, Kenji Hachiuma, Masahiro Ishida, Yoshiki Fukasawa, Yasuhiro Nakai & Jun-ichi Yamaguchi. (2015) Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent. Xenobiotica 45:12, pages 1105-1115.
Read now
André J. Scheen. (2015) SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opinion on Drug Safety 14:12, pages 1879-1904.
Read now
Vlado Perkovic, Meg Jardine, Ujjwala Vijapurkar & Gary Meininger. (2015) Renal effects of canagliflozin in type 2 diabetes mellitus. Current Medical Research and Opinion 31:12, pages 2219-2231.
Read now
James R. Gavin$suffix/text()$suffix/text(), Melanie J. Davies, Michael Davies, Ujjwala Vijapurkar, Maria Alba & Gary Meininger. (2015) The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Current Medical Research and Opinion 31:9, pages 1693-1702.
Read now
Devada Singh-Franco. (2015) Potential for dipeptidyl peptidase-4 inhibitor and sodium glucose cotransporter 2 inhibitor single-pill combinations. Expert Review of Endocrinology & Metabolism 10:3, pages 305-317.
Read now
Kalliopi Pafili & Nikolaos Papanas. (2015) Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?. Expert Opinion on Pharmacotherapy 16:4, pages 453-456.
Read now
Mujahid A Saeed & Parth Narendran. (2014) Dapagliflozin for the treatment of type 2 diabetes: a review of the literature. Drug Design, Development and Therapy 8, pages 2493-2505.
Read now
Yutaka Seino. (2014) Luseogliflozin for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 15:18, pages 2741-2749.
Read now
Steven P Vickers, Sharon C Cheetham, Katie R Headland, Keith Dickinson, Rolf Grempler, Eric Mayoux, Michael Mark & Thomas Klein. (2014) Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes, Metabolic Syndrome and Obesity 7, pages 265-275.
Read now
Louise Kezerle, Leah Shalev & Leonid Barski. (2014) Treating the elderly diabetic patient: special considerations. Diabetes, Metabolic Syndrome and Obesity 7, pages 391-400.
Read now
Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai & Yoshishige Samukawa. (2014) Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Current Medical Research and Opinion 30:7, pages 1245-1255.
Read now
Ubiratan Fabres Machado & Maria Lucia Corrêa-Giannella. (2014) Sodium-glucose transporter 2 inhibitors in type 2 diabetes mellitus: navigating between Scylla and Charybdis. Expert Opinion on Emerging Drugs 19:1, pages 5-9.
Read now
Robert M. Guthrie. (2013) Sodium-Glucose Co-Transporter 2 Inhibitors and the Potential for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Mellitus. Postgraduate Medicine 125:3, pages 21-32.
Read now

Articles from other publishers (180)

Andreas HammerFelix HoferNiema KazemLorenz KollerEva SteinacherUlrike BaumerFelix WollmannAlexandra Kautzky-Willer, Klara BeitlFranziska RemerChristian HengstenbergAlexander NiessnerPatrick Sulzgruber. (2023) Sex-Related Disparities in Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes and Heart Failure. Journal of Women's Health 32:11, pages 1219-1228.
Crossref
Rahul Gupta, Theresa Maitz, David Egeler, Anila Mehta, Mark Nyaeme, Adrija Hajra, Akshay Goel, Jayakumar Sreenivasan, Neel Patel & Wilbert S. Aronow. (2023) SGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure. Trends in Cardiovascular Medicine 33:8, pages 479-486.
Crossref
Benjamin R. Stultz, Matthew W. Ewy & Sarah J. Chalmers. (2023) 53-Year-Old Man With Dyspnea. Mayo Clinic Proceedings 98:11, pages 1697-1701.
Crossref
Andrej Belančić & Sanja Klobučar. (2023) Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms. Diabetology 4:3, pages 251-258.
Crossref
Anna Kochanowska, Przemysław Rusztyn, Karolina Szczerkowska, Stanisław Surma, Aleksandra Gąsecka, Miłosz J. Jaguszewski, Łukasz Szarpak & Krzysztof J. Filipiak. (2023) Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action. Journal of Cardiovascular Development and Disease 10:7, pages 268.
Crossref
Marina Shestakova, Boris Kvasnikov, Ekaterina Erina, Elena Isachenko & Alexander Andreev. (2023) Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial. BMJ Open Diabetes Research & Care 11:3, pages e003290.
Crossref
Mengnan Li, Jian Zhang, Guimei Yang, Jiaxin Zhang, Minmin Han, Yi Zhang & Yunfeng Liu. (2023) Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology 79:6, pages 859-871.
Crossref
Jennifer Ko, Eva Y. Wong, Huyentran N. Tran, Rebecca J.C. Tran & Diana X. Cao. (2023) The glycemic, cholesterol, and weight effects of L-carnitine in diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Epidemiology and Management 10, pages 100122.
Crossref
Zhigui Zheng, Dongyuan He, Jianguo Chen, Xiaohui Xie, Yunan Lu, Binbin Wu & Xinxin Jiang. (2023) Risk of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Treated with Dapagliflozin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinical Drug Investigation 43:4, pages 209-225.
Crossref
Harsha Dissanayake, Shani Dilrukshi, Vithiya Ratnasamy, Pasindu Soysa, Thilina Samarathunga, Prabhath Bandara, Laksara De Silva & Prasad Katulanda. (2023) Empagliflozin in South Asians with type 2 diabetes: Real world data on effects on cardiometabolic parameters, safety and determinants of response to therapy from a diabetes practice in Sri Lanka. Primary Care Diabetes 17:1, pages 98-104.
Crossref
Janina Senn & Stefan Fischli. 2023. Visceral and Ectopic Fat. Visceral and Ectopic Fat 353 361 .
Qian-Long Wu, Ting Zheng, Sheng-Zhen Li, Jin-An Chen, Zi-Chun Xie, Jian-Mei Lai, Ji-Yuan Zeng, Jin-Ting Lin, Jia-Shuan Huang & Min-Hua Lin. (2022) Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome 14:1.
Crossref
Manal M. Alem. (2022) Effect of low dose allopurinol on glycemic control and glycemic variability in patients with type 2 diabetes mellitus: A cross-sectional study. Heliyon 8:11, pages e11549.
Crossref
Chunmei Xu, Liping He, Jing Zhang, Lusi Xu, Jianjun Dong & Lin Liao. (2022) The Cardiovascular Benefits and Infections Risk of SGLT2i versus Metformin in Type 2 Diabetes: A Systemic Review and Meta-Analysis. Metabolites 12:10, pages 979.
Crossref
Panshuang Qiao, Yingli Jia, Ang Ma, Jinzhao He, Chen Shao, Xiaowei Li, Shuyuan Wang, Baoxue Yang & Hong Zhou. (2022) Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice. Frontiers in Pharmacology 13.
Crossref
Yuliya LytvynKaren KimuraNuala PeterVesta LaiJosephine TseLeslie ChamBruce A. PerkinsNima SoleymanlouDavid Z.I. Cherney. (2022) Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition. Circulation 146:6, pages 450-462.
Crossref
Pasquale MoneFahimeh VarzidehStanislovas S. JankauskasAntonella PansiniAngela LombardiSalvatore FrulloneGaetano Santulli. (2022) SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients. Hypertension 79:8, pages 1633-1643.
Crossref
Tingting Liang, Xinqiang Xie, Lei Wu, Longyan Li, Lingshuang Yang, He Gao, Zhenshan Deng, Xiangqian Zhang, Xuefeng Chen, Jumei Zhang, Yu Ding & Qingping Wu. (2022) Comparative analysis of the efficacies of probiotic supplementation and glucose-lowering drugs for the treatment of type 2 diabetes: A systematic review and meta-analysis. Frontiers in Nutrition 9.
Crossref
Naoya Shimizu, Akifumi Ogawa, Akinori Hayashi & Masayoshi Shichiri. (2022) Discordance in the reduction rate between glycated albumin and glycated hemoglobin levels in type 2 diabetes patients receiving SGLT2 inhibitors. Journal of Diabetes and its Complications 36:7, pages 108225.
Crossref
Angeliki M Angelidi, Matthew J Belanger, Alexander Kokkinos, Chrysi C Koliaki & Christos S Mantzoros. (2022) Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. Endocrine Reviews 43:3, pages 507-557.
Crossref
Sumalatha Mahankali, Jagadish Kalava, Yugandhar Garapati, Bullarao Domathoti, Venkata rao Maddumala & Venkatesa Prabhu Sundramurty. (2022) A Treatment to Cure Diabetes Using Plant-Based Drug Discovery. Evidence-Based Complementary and Alternative Medicine 2022, pages 1-12.
Crossref
Omar Azzam, Vance B. Matthews & Markus P. Schlaich. (2022) Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system. Current Opinion in Nephrology & Hypertension 31:2, pages 135-141.
Crossref
Reem M. Hazem, Ahmed Z. Ibrahim, Dina A. Ali & Yasser M. Moustafa. (2022) Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation. International Immunopharmacology 104, pages 108503.
Crossref
Lakshini Y. Herat, Jennifer Matthews, Omar Azzam, Markus P. Schlaich & Vance B. Matthews. (2022) Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition. Current Hypertension Reports 24:3, pages 67-74.
Crossref
Abolfazl Akbari, Mahdi Rafiee, Thozhukat Sathyapalan & Amirhossein Sahebkar. (2022) Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis. Journal of Diabetes Research 2022, pages 1-17.
Crossref
Yoshiki Hiyama, Toyotaka Sato, Satoshi Takahashi, Soh Yamamoto, Noriko Ogasawara, Naoya Masumori & Shin-ichi Yokota. (2022) Reduction of susceptibility to azoles and 5-fluorocytosine and growth acceleration in Candida albicans in glucosuria. Diagnostic Microbiology and Infectious Disease 102:1, pages 115556.
Crossref
Hwee‐Yeong Ng, Foong‐Fah Leung, Wei‐Hung Kuo, Wen‐Chin Lee & Chien‐Te Lee. (2021) Dapagliflozin and xanthine oxidase inhibitors improve insulin resistance and modulate renal glucose and urate transport in metabolic syndrome. Clinical and Experimental Pharmacology and Physiology 48:12, pages 1603-1612.
Crossref
Marc Evans, Angharad R. Morgan, Zaheer Yousef, Gethin Ellis, Umesh Dashora, Dipesh C. Patel, Pam Brown, Wasim Hanif, Johnathan N. Townend, Naresh Kanumilli, Jim Moore, John P. H. Wilding & Stephen C. Bain. (2021) Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. Drugs 81:11, pages 1243-1255.
Crossref
Abdullah M. Alguwaihes. (2021) Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study. Diabetes Therapy 12:7, pages 1979-1992.
Crossref
Isha Sharma, Yingjun Liao, Xiaoping Zheng & Yashpal S. Kanwar. (2021) New Pandemic: Obesity and Associated Nephropathy. Frontiers in Medicine 8.
Crossref
YanLing He, Alok Pachori, Ping Chen, Shenglin Ma, Anisha E. Mendonza, Ahmed Amer, Thomas C. Marbury & Markus Hinder. (2021) Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2, in patients with chronic kidney disease: A randomized trial. Diabetes, Obesity and Metabolism 23:5, pages 1182-1190.
Crossref
Thomas M. Caparrotta, Andrew M. Greenhalgh, Karen Osinski, Robert M. Gifford, Svenja Moser, Sarah H. Wild, Rebecca M. Reynolds, David J. Webb & Helen M. Colhoun. (2021) Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies. Diabetes Therapy 12:4, pages 991-1028.
Crossref
Sachi Singhal & Seema Kumar. (2021) Current Perspectives on Management of Type 2 Diabetes in Youth. Children 8:1, pages 37.
Crossref
Ryan Pelletier, Kelvin Ng, Wajd Alkabbani, Youssef Labib, Nicolas Mourad & John-Michael Gamble. (2021) Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. Therapeutic Advances in Drug Safety 12, pages 204209862198913.
Crossref
Chelsea Baker, Cimmaron Retzik-Stahr, Vatsala Singh, Renee Plomondon, Victoria Anderson & Neda Rasouli. (2021) Should metformin remain the first-line therapy for treatment of type 2 diabetes?. Therapeutic Advances in Endocrinology and Metabolism 12, pages 204201882098022.
Crossref
Kiyohiko Takahashi, Akinobu Nakamura, Sho Furusawa, Kei Yokozeki, Hajime Sugawara, Hideyuki Yanagisawa, Kazumasa Akikawa & Hideaki Kikuchi. (2020) Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria. Journal of Clinical & Translational Endocrinology 22, pages 100244.
Crossref
Alexander H. van Asbeck, Jürgen Dieker, Milou Boswinkel, Johan van der Vlag & Roland Brock. (2020) Kidney-targeted therapies: A quantitative perspective. Journal of Controlled Release 328, pages 762-775.
Crossref
Api Chewcharat, Narut Prasitlumkum, Charat Thongprayoon, Tarun Bathini, Juan Medaura, Saraschandra Vallabhajosyula & Wisit Cheungpasitporn. (2020) Efficacy and Safety of SGLT-2 Inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis. Medical Sciences 8:4, pages 47.
Crossref
C. Berra, R. Manfrini, D. Regazzoli, M.G. Radaelli, O. Disoteo, C. Sommese, P. Fiorina, G. Ambrosio & F. Folli. (2020) Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. Pharmacological Research 160, pages 105052.
Crossref
Anat Fisher, Michael Fralick, Kristian B. Filion, Sophie Dell'Aniello, Antonios Douros, Éric Tremblay, Baiju R. Shah, Paul E. Ronksley, Silvia Alessi‐Severini, Nianping Hu, Shawn C. Bugden, Pierre Ernst & Lisa M. Lix. (2020) Sodium‐glucose co‐transporter‐2 inhibitors and the risk of urosepsis: A multi‐site, prevalent new‐user cohort study. Diabetes, Obesity and Metabolism 22:9, pages 1648-1658.
Crossref
Jessica A. Dominguez Rieg, Jianxiang Xue & Timo Rieg. (2020) Tubular effects of sodium–glucose cotransporter 2 inhibitors: intended and unintended consequences. Current Opinion in Nephrology & Hypertension 29:5, pages 523-530.
Crossref
David M. Williams, Asif Nawaz & Marc Evans. (2020) Diabetes and Novel Coronavirus Infection: Implications for Treatment. Diabetes Therapy 11:9, pages 1915-1924.
Crossref
Emir Muzurović, Siniša Dragnić, Sanja Medenica, Brigita Smolović, Predrag Bulajić & Dimitri P. Mikhailidis. (2020) Weight-centric pharmacological management of type 2 diabetes mellitus – An essential component of cardiovascular disease prevention. Journal of Diabetes and its Complications 34:8, pages 107619.
Crossref
David M. Williams, Asif Nawaz & Marc Evans. (2020) Drug Therapy in Obesity: A Review of Current and Emerging Treatments. Diabetes Therapy 11:6, pages 1199-1216.
Crossref
Shital P. Patil, Ashutosh Goswami, Kiran Kalia & Abhijeet S. Kate. (2019) Plant-Derived Bioactive Peptides: A Treatment to Cure Diabetes. International Journal of Peptide Research and Therapeutics 26:2, pages 955-968.
Crossref
David R Powell, Brian Zambrowicz, Linda Morrow, Carine Beysen, Marcus Hompesch, Scott Turner, Marc Hellerstein, Phillip Banks, Paul Strumph & Pablo Lapuerta. (2020) Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption. The Journal of Clinical Endocrinology & Metabolism 105:4, pages e1235-e1249.
Crossref
Silvia Maestroni & Gianpaolo Zerbini. 2020. Microvascular Disease in Diabetes. Microvascular Disease in Diabetes 97 109 .
Hirohito Sone, Tatsuroh Kaneko, Kosuke Shiki, Yoshifumi Tachibana, Egon Pfarr, Jisoo Lee & Naoko Tajima. (2019) Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial. Diabetes, Obesity and Metabolism 22:3, pages 417-426.
Crossref
Vasilios Kotsis, Jens Jordan, Stella Stabouli, Christina Antza, Dragan Micic, Bojan Jelaković, Markus P. Schlaich, Peter M. Nilsson, Reinhold Kreutz, Giuseppe Mancia, Kostas Tsioufis & Guido Grassi. (2020) Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. Journal of Hypertension 38:3, pages 377-386.
Crossref
Sunam M. Sujanani, Mohanad M. Elfishawi, Paria Zarghamravanbaksh, Francisco J. Cuevas Castillo & David M. Reich. (2020) Dapagliflozin-Induced Acute Pancreatitis: A Case Report and Review of Literature. Case Reports in Endocrinology 2020, pages 1-4.
Crossref
Canan ERSOY. (2020) SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control. Turkish Journal of Internal Medicine 2:1, pages 1-4.
Crossref
Wayne Huey-Herng Sheu, Siew Pheng ChanBien J. MatawaranChaicharn DeerochanawongAmbrish MithalJuliana ChanKetut SuastikaChin Meng KhooHuu Man NguyenJi LinongAndrea LukKun-Ho Yoon. (2020) Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations. Diabetes & Metabolism Journal 44:1, pages 11.
Crossref
A. Gal, S.E. Burton, K. Weidgraaf, P. Singh, N. Lopez-Villalobos, A. Jacob, U. Malabu & R. Burchell. (2020) The effect of the sodium-glucose cotransporter type-2 inhibitor dapagliflozin on glomerular filtration rate in healthy cats. Domestic Animal Endocrinology 70, pages 106376.
Crossref
Sanaz Kamalinia, Robert G. Josse, Patrick J. Donio, Lindsay Leduc, Baiju R. Shah & Sheldon W. Tobe. (2019) Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis. Endocrinology, Diabetes & Metabolism 3:1.
Crossref
Kashif Haider, Ankita Pathak, Ankit Rohilla, Md Rafi Haider, Kamal Ahmad & M. Shahar Yar. (2019) Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review. European Journal of Medicinal Chemistry 184, pages 111773.
Crossref
Dhiren K. Patel & Jodi Strong. (2019) The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit. Diabetes Therapy 10:5, pages 1771-1792.
Crossref
Munehisa Bekki, Nobuhiro Tahara, Atsuko Tahara, Sachiyo Igata, Akihiro Honda, Yoichi Sugiyama, Tomohisa Nakamura, Jiahui Sun, Yuki Kumashiro, Takanori Matsui, Yoshihiro Fukumoto & Sho-ichi Yamagishi. (2019) Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study. Current Vascular Pharmacology 17:4, pages 411-420.
Crossref
Giovanni Musso, Roberto Gambino, Maurizio Cassader & Elena Paschetta. (2019) Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ, pages l1328.
Crossref
Kai Zhang, Bizhen Xue, Yuexing Yuan & Yao Wang. (2019) Correlation of Serum 1,5-AG with Uric Acid in Type 2 Diabetes Mellitus with Different Renal Functions. International Journal of Endocrinology 2019, pages 1-7.
Crossref
Caroline K. Kramer & Bernard Zinman. (2019) Sodium–Glucose Cotransporter–2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes. Annual Review of Medicine 70:1, pages 323-334.
Crossref
Aleksandra Novikov, Yiling Fu, Winnie Huang, Brent Freeman, Rohit Patel, Charlotte van Ginkel, Hermann Koepsell, Meinrad Busslinger, Akira Onishi, Josselin Nespoux & Volker Vallon. (2019) SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. American Journal of Physiology-Renal Physiology 316:1, pages F173-F185.
Crossref
Yong Zhang, Yuping Zhang, Kun Sun, Ziyi Meng & Ligong Chen. (2019) The SLC transporter in nutrient and metabolic sensing, regulation, and drug development. Journal of Molecular Cell Biology 11:1, pages 1-13.
Crossref
Solomon Habtemariam. 2019. Medicinal Foods as Potential Therapies for Type-2 Diabetes and Associated Diseases. Medicinal Foods as Potential Therapies for Type-2 Diabetes and Associated Diseases 13 39 .
Shuai Li, Nan Wang, Xiaochen Guo, Junyan Li, Teng Zhang, Guiping Ren & Deshan Li. (2018) Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption. Biomedicine & Pharmacotherapy 108, pages 355-366.
Crossref
Josá G. Jiménez-Montero, Christopher J. Mora-Aguilar & Chih Hao Chen-Ku. (2018) Diabetic Ketoacidosis in a Patient with Type 1 Diabetes Mellitus Treated with Low Insulin in Combination with Empagliflozin. AACE Clinical Case Reports 4:6, pages e505-e508.
Crossref
İrfan Karahan, Çağar Alp & Aşkın Güngüneş. (2018) Sodium-glucose co-transporter-2 inhibitors in Type 2 diabetes treatment. Ortadoğu Tıp Dergisi 10:3, pages 381-385.
Crossref
Hiroyuki Takashima, Yoshinori Yoshida, Chinami Nagura, Tetsuya Furukawa, Ritsukou Tei, Takashi Maruyama, Noriaki Maruyama & Masanori Abe. (2018) Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial. Diabetes and Vascular Disease Research 15:5, pages 469-472.
Crossref
H. Sims, K. H. Smith, P. Bramlage & J. Minguet. (2018) Sotagliflozin: a dual sodium‐glucose co‐transporter‐1 and ‐2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus. Diabetic Medicine 35:8, pages 1037-1048.
Crossref
Hao Li, Fang-Hong Shi, Shi-Ying Huang, Shun-Guo Zhang & Zhi-Chun Gu. (2018) Clinical adverse effects of sodium-glucose cotransporter 2 inhibitors. Medicine 97:32, pages e11853.
Crossref
Akira Mima. (2018) Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. Journal of Diabetes and its Complications 32:7, pages 720-725.
Crossref
Caroline L. Benn, Pinky Dua, Rachel Gurrell, Peter Loudon, Andrew Pike, R. Ian Storer & Ciara Vangjeli. (2018) Physiology of Hyperuricemia and Urate-Lowering Treatments. Frontiers in Medicine 5.
Crossref
Matteo Monami, Francesco Liistro, Alessia Scatena, Besmir Nreu & Edoardo Mannucci. (2018) Short and medium‐term efficacy of sodium glucose co‐transporter‐2 (SGLT‐2) inhibitors: A meta‐analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 20:5, pages 1213-1222.
Crossref
Robert Puckrin, Marie-Philippe Saltiel, Pauline Reynier, Laurent Azoulay, Oriana H. Y. Yu & Kristian B. Filion. (2018) SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetologica 55:5, pages 503-514.
Crossref
Yumo Zhao, Lubin Xu, Dongli Tian, Peng Xia, Hua Zheng, Li Wang & Limeng Chen. (2017) Effects of sodium‐glucose co‐transporter 2 ( SGLT2 ) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials . Diabetes, Obesity and Metabolism 20:2, pages 458-462.
Crossref
Jian Li, Ying-hong Shao, Xiao-gang Wang, Yanping Gong, Chunlin Li & Yanhui Lu. (2018) Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis. Endocrine Journal 65:3, pages 335-344.
Crossref
David Z.I. Cherney, Mark E. Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl & Søren S. Lund. (2018) Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney International 93:1, pages 231-244.
Crossref
Alexandros Briasoulis, Omar Al Dhaybi & George L. Bakris. (2018) SGLT2 Inhibitors and Mechanisms of Hypertension. Current Cardiology Reports 20:1.
Crossref
James Xu & Rohan Rajaratnam. (2017) Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. Cardiovascular Diabetology 16:1.
Crossref
G.P. Fadini, G. Zatti, A. Consoli, E. Bonora, G. Sesti, A. Avogaro, A. Consoli, G. Formoso, D. Antenucci, G. Grossi, A. Pucci, G. Sesti, F. Andreozzi, L. Indrieri, G. Capobianco, A. Gatti, R. Bonadonna, I. Zavaroni, A. Dei Cas, G. Felace, P. Li Volsi, R. Buzzetti, G. Leto, F. D'Angelo, S. Morano, A. Giaccari, G. Sorice, E. Orsi, A. Carlo Bossi, F. Querci, E. Duratorre, C. Malagola, I. Franzetti, P. Silvia Morpurgo, M. Boemi, M. Petrelli, G. Aimaretti, I. Karamouzis, F. Cavalot, G. Saglietti, G. Gruden, E. Devangelio, G. Cazzetta, O. Lamacchia, S. Cervone, L. Frittitta, S. Arena, A. Di Benedetto, S. Piro, C. Giordano, M. Rizzo, R. Chianetta, C. Mannina, A. Solini, A. Natali, R. Anichini, F. Dotta, B. Fattor, A. Avogaro, G.P. Fadini, E. Bonora, M. Cigolini, N. Simioni, V. Frison, M. Poli, A. Lapolla, N. Cristiano Chilelli & C. Vinci. (2017) Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes). Nutrition, Metabolism and Cardiovascular Diseases 27:12, pages 1089-1097.
Crossref
Jian Li, Yanping Gong, Chunlin Li, Yanhui Lu, Yu Liu & Yinghong Shao. (2017) Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus. Medicine 96:27, pages e7201.
Crossref
Wassim Mosleh, Abhinav Sharma, Mandeep S. Sidhu, Brian Page, Umesh C. Sharma & Michael E. Farkouh. (2017) The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease. Cardiovascular Drugs and Therapy 31:3, pages 311-318.
Crossref
Oluwaranti F. Akiyode & Adebola A. Adesoye. (2016) Adverse Effects Associated With Newer Diabetes Therapies. Journal of Pharmacy Practice 30:2, pages 238-244.
Crossref
Takanori Kumagai, Tatsuru Ota, Yoshifuru Tamura, Wen Xiu Chang, Shigeru Shibata & Shunya Uchida. (2016) Time to target uric acid to retard CKD progression. Clinical and Experimental Nephrology 21:2, pages 182-192.
Crossref
Giuseppe Maltese, Paraskevi-Maria Psefteli, Benedetta Rizzo, Salil Srivastava, Luigi Gnudi, Giovanni E. Mann & Richard C.M. Siow. (2017) The anti-ageing hormone klotho induces Nrf2-mediated antioxidant defences in human aortic smooth muscle cells. Journal of Cellular and Molecular Medicine 21:3, pages 621-627.
Crossref
Hermann Koepsell. (2017) The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacology & Therapeutics 170, pages 148-165.
Crossref
Yaeni Kim & Cheol Whee Park. (2017) New therapeutic agents in diabetic nephropathy. The Korean Journal of Internal Medicine 32:1, pages 11-25.
Crossref
Fumiaki Obata, Kenji Tani, Harutaka Yamaguchi, Ryo Tabata, Hiroyasu Bando & Issei Imoto. (2017) Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus: a pilot trial. The Journal of Medical Investigation 64:1.2, pages 50-57.
Crossref
Jenna M. LeRoy & Samuel J. Stellpflug. 2017. Critical Care Toxicology. Critical Care Toxicology 1363 1386 .
Nicole P Albanese. (2016) Clinical Use of SGLT-2 Inhibitors for the Management of Type 2 Diabetes in a Patient Centered Medical Home. Journal of Diabetes, Metabolic Disorders & Control 3:8.
Crossref
Heidi Storgaard, Lise L. Gluud, Cathy Bennett, Magnus F. Grøndahl, Mikkel B. Christensen, Filip K. Knop & Tina Vilsbøll. (2016) Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLOS ONE 11:11, pages e0166125.
Crossref
E. Benetti, R. Mastrocola, G. Vitarelli, J. C. Cutrin, D. Nigro, F. Chiazza, E. Mayoux, M. Collino & R. Fantozzi. (2016) Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation. Journal of Pharmacology and Experimental Therapeutics 359:1, pages 45-53.
Crossref
Yuliya Lytvyn, Petter Bjornstad, Nicole Pun & David Z.I. Cherney. (2016) New and old agents in the management of diabetic nephropathy. Current Opinion in Nephrology and Hypertension 25:3, pages 232-239.
Crossref
Louise Curtis, Malik Asif Humayun, James Walker, Kerri Hampton & Helen Partridge. (2016) Addition of SGLT2 inhibitor to GLP-1 agonist therapy in people with type 2 diabetes and suboptimal glycaemic control. Practical Diabetes 33:4, pages 129-132.
Crossref
Sho-ichi YamagishiTakanori Matsui. (2016) Protective Role of Sodium–Glucose Co-Transporter 2 Inhibition Against Vascular Complications in Diabetes. Rejuvenation Research 19:2, pages 107-114.
Crossref
Yu Zhao, Peng Gao, Fang Sun, Qiang Li, Jing Chen, Hao Yu, Li Li, Xing Wei, Hongbo He, Zongshi Lu, Xiao Wei, Bin Wang, Yuanting Cui, Shiqiang Xiong, Qianhui Shang, Aimin Xu, Yu Huang, Daoyan Liu & Zhiming Zhu. (2016) Sodium Intake Regulates Glucose Homeostasis through the PPARδ/Adiponectin-Mediated SGLT2 Pathway. Cell Metabolism 23:4, pages 699-711.
Crossref
Gary C.W. Chan & Sydney C.W. Tang. (2016) Diabetic nephropathy: landmark clinical trials and tribulations. Nephrology Dialysis Transplantation 31:3, pages 359-368.
Crossref
Harindra Rajasekeran, Yuliya Lytvyn & David Z.I. Cherney. (2016) Sodium–glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney International 89:3, pages 524-526.
Crossref
Kai He, Shanghua Song, Zongyao Zou, Min Feng, Dezhen Wang, Yanzhi Wang, Xuegang Li & Xiaoli Ye. (2016) The Hypoglycemic and Synergistic Effect of Loganin, Morroniside, and Ursolic Acid Isolated from the Fruits of Cornus officinalis . Phytotherapy Research 30:2, pages 283-291.
Crossref
Michelle Lam & Adrian Coleman. (2016) Use of a sodium–glucose cotransporter 2 inhibitor in a patient with chronic kidney disease. Journal of Renal Nursing 8:1, pages 20-23.
Crossref
Sydney C.W. Tang, Gary C.W. Chan & Kar Neng Lai. (2016) Recent advances in managing and understanding diabetic nephropathy. F1000Research 5, pages 1044.
Crossref
Kathryn M. Thrailkill, R. Clay Bunn, Jeffry S. Nyman, Mallikarjuna R. Rettiganti, Gael E. Cockrell, Elizabeth C. Wahl, Sasidhar Uppuganti, Charles K. LumpkinJr.Jr. & John L. Fowlkes. (2016) SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice. Bone 82, pages 101-107.
Crossref
Jenna M. LeRoy & Samuel J. Stellpflug. 2016. Critical Care Toxicology. Critical Care Toxicology 1 25 .
Jeffrey H. William, Holly Kramer & Sylvia E. Rosas. 2016. Metabolic Syndrome. Metabolic Syndrome 761 780 .
Nobutaka Nakamura, Takanori Matsui, Yuji Ishibashi & Sho-ichi Yamagishi. (2015) Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation. Diabetology & Metabolic Syndrome 7:1.
Crossref
Christian Mende. (2015) Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy. Advances in Therapy 32:12, pages 1177-1191.
Crossref
Bruce A. Perkins, David Z. I. Cherney, Nima Soleymanlou, Justin A. Lee, Helen Partridge, Holly Tschirhart, Bernard Zinman, Roger Mazze, Nora Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C. Broedl & Odd Erik Johansen. (2015) Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes. PLOS ONE 10:11, pages e0141085.
Crossref
Diego García-Compeán, José A. González-González, Fernando J. Lavalle-González, Emmanuel I. González-Moreno, Héctor J. Maldonado-Garza & Jesús Z. Villarreal-Pérez. (2015) The treatment of diabetes mellitus of patients with chronic liver disease. Annals of Hepatology 14:6, pages 780-788.
Crossref
Xiang-Yang Liu, Ning Zhang, Rui Chen, Jia-Guo Zhao & Pei Yu. (2015) Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. Journal of Diabetes and its Complications 29:8, pages 1295-1303.
Crossref
Thomas Forst & Christoph KaptizaRüdiger Göke & Burkhard Göke. 2015. Clinical Advances in Diabetes Mellitus. Clinical Advances in Diabetes Mellitus 50 57 .
J. Rosenstock, A. Jelaska, C. Zeller, G. Kim, U. C. Broedl & H. J. Woerle. (2015) Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial. Diabetes, Obesity and Metabolism 17:10, pages 936-948.
Crossref
Petter Bjornstad, Miguel A. Lanaspa, Takuji Ishimoto, Tomoki Kosugi, Shinji Kume, Diana Jalal, David M. Maahs, Janet K. Snell-Bergeon, Richard J. Johnson & Takahiko Nakagawa. (2015) Fructose and uric acid in diabetic nephropathy. Diabetologia 58:9, pages 1993-2002.
Crossref
R. Nishimura, T. Osonoi, S. Kanada, H. Jinnouchi, K. Sugio, H. Omiya, M. Ubukata, S. Sakai & Y. Samukawa. (2015) Effects of luseogliflozin, a sodium–glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in J apanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled, crossover study . Diabetes, Obesity and Metabolism 17:8, pages 800-804.
Crossref
George Dailey. (2015) Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on P hase 3 trials 艾格列净治疗2型糖尿病：基于3期试验的安全性与有效性概述 . Journal of Diabetes 7:4, pages 448-461.
Crossref
Pol Sanz-Serra, Juan Pedro-Botet, Juana A. Flores-Le Roux, David Benaiges & Juan J. Chillarón. (2015) Dapagliflozina: Más allá del control glucémico en el tratamiento de la diabetes mellitus tipo 2. Clínica e Investigación en Arteriosclerosis 27:4, pages 205-211.
Crossref
John D Stokes. (2015) Looking Into the Future of Diabetes Care with the Sodium Glucose Co-Transporter-2 Inhibitors. Endocrinology&Metabolism International Journal 2:2.
Crossref
J. A. Lovshin & R. E. Gilbert. (2015) Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?. Current Hypertension Reports 17:6.
Crossref
Linda A Gallo, Ernest M Wright & Volker Vallon. (2015) Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences. Diabetes and Vascular Disease Research 12:2, pages 78-89.
Crossref
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L. Peters, Apostolos Tsapas, Richard Wender & David R. Matthews. (2015) Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58:3, pages 429-442.
Crossref
David R. Powell, Melinda G. Smith, Deon D. Doree, Angela L. Harris, Wendy W. Xiong, Faika Mseeh, Alan Wilson, Suma Gopinathan, Damaris Diaz, Nicole C. Goodwin, Bryce Harrison, Eric Strobel, David B. Rawlins, Ken Carson, Brian Zambrowicz & Zhi‐Ming Ding. (2015) LP ‐925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT 1 and SGLT 2 . Pharmacology Research & Perspectives 3:2.
Crossref
S. Parikh, J. Wilding, S. Jabbour & E. Hardy. (2015) Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice 69:2, pages 186-198.
Crossref
N. N. Hamouda, V. Sydorenko, M. A. Qureshi, J. M. Alkaabi, M. Oz & F. C. Howarth. (2014) Dapagliflozin reduces the amplitude of shortening and Ca2+ transient in ventricular myocytes from streptozotocin-induced diabetic rats. Molecular and Cellular Biochemistry 400:1-2, pages 57-68.
Crossref
Toshimi ImaiTetsu AkimotoChiharu ItoTakahiro MasudaDaisuke Nagata. (2015) Management of Diabetes Associated with Nephrotic Syndrome: Therapeutic Potential of Dapagliflozin for Protracted Volume Retention. Drug Target Insights 9, pages DTI.S31710.
Crossref
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L. Peters, Apostolos Tsapas, Richard Wender & David R. Matthews. (2015) Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:1, pages 140-149.
Crossref
L. Zanoli, A. Granata, P. Lentini, S. Rastelli, P. Fatuzzo, F. Rapisarda & P. Castellino. (2015) Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease. The Scientific World Journal 2015, pages 1-6.
Crossref
Marko Škrtić & David Z.I. Cherney. (2015) Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Current Opinion in Nephrology and Hypertension 24:1, pages 96-103.
Crossref
S. Franc & G. Charpentier. (2015) Inhibiteurs du SGLT2. Résultats des études cliniques de phase III : Effets glycémiques, pondéraux et tensionnels. Médecine des Maladies Métaboliques 9:1, pages S30-S40.
Crossref
André J. Scheen. (2014) Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Drugs 75:1, pages 33-59.
Crossref
Harald Rupprecht. (2015) Welchen Stellenwert haben SGLT-2-Blocker?. MMW - Fortschritte der Medizin 157:1, pages 55-60.
Crossref
Jeffrey H. William, Holly Kramer & Sylvia E. Rosas. 2014. Metabolic Syndrome. Metabolic Syndrome 1 24 .
Sylvia E. Rosas, Jeffrey H. William & Holly Kramer. 2014. Metabolic Syndrome. Metabolic Syndrome 1 24 .
Michelle Orme, Peter Fenici, Isabelle Duprat Lomon, Gail Wygant, Rebecca Townsend & Marina Roudaut. (2014) A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy. Diabetology & Metabolic Syndrome 6:1.
Crossref
B Haas, N Eckstein, V Pfeifer, P Mayer & M D S Hass. (2014) Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutrition & Diabetes 4:11, pages e143-e143.
Crossref
A. Liakos, T. Karagiannis, E. Athanasiadou, M. Sarigianni, M. Mainou, K. Papatheodorou, E. Bekiari & A. Tsapas. (2014) Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism 16:10, pages 984-993.
Crossref
Richard E. Gilbert. (2014) Sodium–glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?. Kidney International 86:4, pages 693-700.
Crossref
David Z.I. Cherney & Bruce A. Perkins. (2014) Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: Simultaneous Glucose Lowering and Renal Protection?. Canadian Journal of Diabetes 38:5, pages 356-363.
Crossref
Xu-Ping Yang, Dan Lai, Xiao-Yan Zhong, Hong-Ping Shen & Yi-Lan Huang. (2014) Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. European Journal of Clinical Pharmacology 70:10, pages 1149-1158.
Crossref
Matt Hrapchak, Bachir Latli, Xiao-Jun Wang, Heewon Lee, Scot Campbell, Jinhua J. Song & Chris H. Senanayake. (2014) Synthesis of empagliflozin, a novel and selective sodium-glucose co-transporter-2 inhibitor, labeled with carbon-14 and carbon-13. Journal of Labelled Compounds and Radiopharmaceuticals 57:12, pages 687-694.
Crossref
William T. Cefalu, John B. Buse, Stefano Del Prato, Philip D. HomeDerek LeRoith, Michael A. Nauck, Itamar Raz, Julio Rosenstock & Matthew C. Riddle. (2014) Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. Diabetes Care 37:9, pages 2647-2659.
Crossref
Qian Zhang, Jingtao Dou & Juming Lu. (2014) Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: Systematic review and meta-analyses. Diabetes Research and Clinical Practice 105:3, pages 313-321.
Crossref
Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller, Gabriel Kim, Hans J Woerle & Uli C Broedl. (2014) Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. The Lancet Diabetes & Endocrinology 2:9, pages 691-700.
Crossref
H. Storgaard, L. L. Gluud, M. Christensen, F. K. Knop & T. Vilsboll. (2014) The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials. BMJ Open 4:8, pages e005378-e005378.
Crossref
David R. Powell, Christopher M. DaCosta, Melinda Smith, Deon Doree, Angela Harris, Lindsey Buhring, William Heydorn, Amr Nouraldeen, Wendy Xiong, Padmaja Yalamanchili, Faika Mseeh, Alan Wilson, Melanie Shadoan, Brian Zambrowicz & Zhi-Ming Ding. (2014) Effect of LX4211 on Glucose Homeostasis and Body Composition in Preclinical Models. Journal of Pharmacology and Experimental Therapeutics 350:2, pages 232-242.
Crossref
Julio Rosenstock, Ante Jelaska, Guillaume Frappin, Afshin Salsali, Gabriel Kim, Hans J. Woerle & Uli C. Broedl. (2014) Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes Care 37:7, pages 1815-1823.
Crossref
M. Suzuki, M. Hiramatsu, M. Fukazawa, M. Matsumoto, K. Honda, Y. Suzuki & Y. Kawabe. (2014) Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans . Diabetes, Obesity and Metabolism 16:7, pages 622-627.
Crossref
Luca De Nicola, Francis B. Gabbai, Maria Elena Liberti, Adelia Sagliocca, Giuseppe Conte & Roberto Minutolo. (2014) Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes. American Journal of Kidney Diseases 64:1, pages 16-24.
Crossref
Merlin C. Thomas. (2014) Renal effects of dapagliflozin in patients with type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism 5:3, pages 53-61.
Crossref
Gandahari Rosa A. Carpio & Vivian A. Fonseca. (2014) Update on Safety Issues Related to Antihyperglycemic Therapy. Diabetes Spectrum 27:2, pages 92-100.
Crossref
Bruce A. Perkins, David Z.I. Cherney, Helen Partridge, Nima Soleymanlou, Holly Tschirhart, Bernard Zinman, Nora M. Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C. Broedl & Odd-Erik Johansen. (2014) Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial. Diabetes Care 37:5, pages 1480-1483.
Crossref
M. Monami, C. Nardini & E. Mannucci. (2014) Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 16:5, pages 457-466.
Crossref
S. Goring, N. Hawkins, G. Wygant, M. Roudaut, R. Townsend, I. Wood & A. H. Barnett. (2014) Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes, Obesity and Metabolism 16:5, pages 433-442.
Crossref
J.J. Gorgojo-Martínez. (2014) Nuevos fármacos antidiabéticos: avanzando hacia el control integral de la diabesidad. Hipertensión y Riesgo Vascular 31:2, pages 45-57.
Crossref
Mei Zhang, Lin Zhang, Bin Wu, Haolan Song, Zhenmei An & Shuangqing Li. (2014) Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes/Metabolism Research and Reviews 30:3, pages 204-221.
Crossref
David Z.I. CherneyBruce A. PerkinsNima SoleymanlouMaria MaioneVesta LaiAlana LeeNora M. FaganHans J. WoerleOdd Erik JohansenUli C. BroedlMaximilian von Eynatten. (2014) Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus. Circulation 129:5, pages 587-597.
Crossref
Edward C. Chao. (2014) SGLT-2 Inhibitors: A New Mechanism for Glycemic Control. Clinical Diabetes 32:1, pages 4-11.
Crossref
Yu-nan Sun, Yi Zhou, Xi Chen, Wen-si Che & Siu-wai Leung. (2013) The efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials. Systematic Reviews 2:1.
Crossref
Asres Berhan & Alex Barker. (2013) Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocrine Disorders 13:1.
Crossref
J. Rosenstock, L. J. Seman, A. Jelaska, S. Hantel, S. Pinnetti, T. Hach & H. J. Woerle. (2013) Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes, Obesity and Metabolism 15:12, pages 1154-1160.
Crossref
Elliott M. Groves, Katherine Yu, Nathan D. Wong & Shaista Malik. (2013) Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes Mellitus. Current Treatment Options in Cardiovascular Medicine 15:6, pages 706-721.
Crossref
Minara Shamkhalovna Shamkhalova, Ivona Renata Yarek-Martynova, Natalya Petrovna Trubitcyna & Marina Vladimirovna Shestakova. (2013) Glucose-lowering therapies in patients with diabetes mellitus and chronic kidney disease. Diabetes mellitus 16:3, pages 97-102.
Crossref
Motoshi Ouchi, Kenzo Oba, Junya Aoyama, Kentaro Watanabe, Kazuhito Ishii, Hiroyuki Yano, Masayuki Motoyama, Ken-ichi Sekimizu, Noriaki Matsumura, Yoshimasa Igari, Tatsuya Suzuki & Hiroshi Nakano. (2013) Serum uric acid in relation to serum 1,5-anhydroglucitol levels in patients with and without type 2 diabetes mellitus. Clinical Biochemistry 46:15, pages 1436-1441.
Crossref
. (2013) ▼Dapagliflozin (Forxiga) for type 2 diabetes?:. Drug and Therapeutics Bulletin 51:9, pages 105-108.
Crossref
Wenhui Zhang, Walter J. J. Krauwinkel, James Keirns, Robert W. Townsend, Kenneth C. Lasseter, Lisa Plumb, Takeshi Kadokura, Fumihiko Ushigome & Ronald Smulders. (2013) The Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Ipragliflozin, a Novel Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor. Clinical Drug Investigation 33:7, pages 489-496.
Crossref
Ma'en Al‐Mrayat & Monica Vloemans. (2013) Dapagliflozin: NICE guidance for use in combination therapy for the treatment of type 2 diabetes. Practical Diabetes 30:6, pages 218-220.
Crossref
Pablo Lapuerta, Julio Rosenstock, Brian Zambrowicz, David R. Powell, Ike Ogbaa, Joel Freiman, William T. Cefalu, Phillip Banks, Kenny Frazier, Mike Kelly & Arthur Sands. (2013) Study Design and Rationale of a Dose-Ranging Trial of LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy. Clinical Cardiology 36:7, pages 367-371.
Crossref
Thorsten Siegmund. (2013) Kardiovaskuläre Hochrisikopatienten mit Diabetes mellitus. CardioVasc 13:3, pages 36-44.
Crossref
S. Martin. (2013) Inhibition des natriumabhängigen Glukosetransporter 2Inhibition of sodium-glucose cotransporter 2. Der Diabetologe 9:4, pages 289-295.
Crossref
Anke Tönjes & Peter Kovacs. (2013) SGLT2 : a potential target for the pharmacogenetics of Type 2 diabetes? . Pharmacogenomics 14:7, pages 825-833.
Crossref
Jan N. Basile. (2013) The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). Journal of Diabetes and its Complications 27:3, pages 280-286.
Crossref
Koji Yamaguchi, Motohiro Kato, Masayuki Suzuki, Hitoshi Hagita, Maiko Takada, Miho Ayabe, Yoshinori Aso, Masaki Ishigai & Sachiya Ikeda. (2013) In Vitro–In Vivo Correlation of the Inhibition Potency of Sodium-Glucose Cotransporter Inhibitors in Rat: A Pharmacokinetic and Pharmacodynamic Modeling Approach. Journal of Pharmacology and Experimental Therapeutics 345:1, pages 52-61.
Crossref
Usha Panchapakesan, Kate Pegg, Simon Gross, Muralikrishna Gangadharan Komala, Harshini Mudaliar, Josephine Forbes, Carol Pollock & Amanda Mather. (2013) Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?. PLoS ONE 8:2, pages e54442.
Crossref
K. H. Williams, N. A. Shackel, M. D. Gorrell, S. V. McLennan & S. M. Twigg. (2013) Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo. Endocrine Reviews 34:1, pages 84-129.
Crossref
Monika Misra. (2013) SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. Journal of Pharmacy and Pharmacology 65:3, pages 317-327.
Crossref
Michael Lehrke & Nikolaus Marx. (2012) New antidiabetic therapies. Current Opinion in Lipidology 23:6, pages 569-575.
Crossref

Displaying 200 of 207 citing articles. Use the download link below to view the full list of citing articles.

Download full citations list

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.